Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A collaboration of 10 healthcare research organizations has demonstrated that real-world endpoints can be used to describe patient outcomes that are analogous to results generated through conventional endpoints in clinical trials.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Associate Editor
In This Issue

YOU MAY BE INTERESTED IN

Associate Editor

Login